"Sucanon is one of
only three drugs approved anywhere in the world, belonging to
a new category of drugs called 'insulin sensitizers'."
Overview
Biotech Holdings Ltd. is an integrated
pharmaceutical company based in Vancouver, Canada, engaged in
research, development, manufacture and marketing of
pharmaceutical products.
The focus of the Company is the manufacturing
and international marketing of SucanonTM, a new drug for the
treatment of Type II Diabetes.
Type II Diabetes affects more than 18 million
people in North America, over 20 million in Latin America and
over 150 million worldwide
Investment Highlights
- Sucanon is one of only three drugs approved anywhere
in the world, belonging to a new category of drugs called
"insulin sensitizers".
- Sucanon has received regulatory approval in Mexico.
Mexico is the eighth largest pharmaceutical market and one
of the largest diabetic markets in the world.
Complications of diabetes is Mexico's leading cause of
death.
- Sales of the drug began in Mexico in early 2005.
Sucanon is now sold in more than 600 stores nationally in
Mexico including outlets of at least six drugstore chains.
- Sucanon has been approved in Peru and sales are
planned to begin later this year. Preliminary distribution
agreements for Sucanon have been negotiated in other Latin
American countries.
- Internet sales of Sucanon are also planned.
Clinical Information
- Clinical studies involving three hospitals and 1,500
patients were completed in China.
- A high satisfaction rate was indicated by a
post-clinical trial poll and by follow-up data on 7,600
patients, reported in 2001. The results in patients
receiving Sucanon administration indicated:
- Significantly reduced symptomatology of disease
- A toxicity profile that was difficult to distinguish
from placebo
- Significantly reduced hyperglycemia and glycosuria
- Significantly reduced hypercholesteraloemia &
tryglyceridemia
- A very high level of patient acceptability
- Significantly improved quality of life
- In preparation for regulatory applications to be made
throughout Latin America, a supplementary and confirming
trial was carried out in Brazil.
- Sucanon is taken one tablet, twice daily, orally.
Product Information
Sucanon acts to increase the body's ability to
utilize its insulin, resulting in improved metabolism and an
enhanced sense of well-being for the patient. This increased
insulin sensitivity results in decreased blood sugar levels in
those suffering from Type II Diabetes. Sucanon is one of only
three drugs approved anywhere in the world, belonging to a new
category of drugs called "insulin sensitizers".
1. Insulin binding to receptors and
entering the cell, (which is impeded in NIDDM patients), is
essential for the uptake of glucose 2. Sucanon
increases the binding of insulin to its receptors 3.
Sucanon increases the internalization of insulin 4. As
a result, Sucanon increases the intracellular level of
insulin, which then increases the uptake of glucose .
Type II Diabetes
Type II Diabetes, or Non-Insulin Dependent
Diabetes Mellitus (NIDDM), is the most common form of
Diabetes. While Type I or Insulin-Dependent Diabetes typically
becomes evident in childhood and is due to an inborn lack or
complete absence of insulin production, Type II Diabetes
typically becomes evident in adulthood and is significantly
due to the patient's lifestyle. Of all diabetics, 85% to 90%
are Type II. In many countries, the incidence of Type II
Diabetes has been rising sharply in recent decades, while the
average age of onset has been declining. Type II Diabetes
affects more than 17 million people in North America, over 20
million in Latin America and over 150 million worldwide.
Marketing
Marketing and distribution of Sucanon has been discussed with strong
pharmaceutical partners in Argentina, Brazil, Chile, and
Venezuela, with other key Latin American markets expected to
follow. Developments are expected in the current year. Also,
discussions are underway to identify a suitable development
partner for North American and Western European markets.
Production
Production of Sucanon key ingredients is carried out at Biotech's plant
in suburban Vancouver, tableting and packaging is done in
Mexico City.
• Biotech Holdings announces investor awareness program with
AllPennyStocks.com
PR Newswire (Tue, Apr 19)
• Sucanon Diabetes drug infomercial on Biotech Holdings
website
PR Newswire (Mon, Apr 18)
• Biotech Holdings receives offer for $500,000 USD ($610,000
Cdn) funding
PR Newswire (Tue, Apr 12)
• Biotech Holdings retains corporate development company
PR Newswire (Mon, Apr 11)
• Sucanon Distribution Expands in Mexico
PR Newswire (Thu, Mar 31)
• Sucanon Television Advertising and Information Pamphlet
Receives Regulatory Approval
PR Newswire (Thu, Mar 10)
• Biotech Holdings Increases Retail Outlets Selling Sucanon,
Receives Infomercial Approval
PR Newswire (Thu, Mar 3)
• Biotech Begins Advertising of Sucanon in Mexico
Business Wire (Thu, Jan 20)
Management Team
President. Robert B. Rieveley. BCom
Robert Rieveley is the founding shareholder of
Biotech Holdings. He has raised over $10 million for Biotech
and is primarily responsible for the direction of the company.
He has 15 years experience in the development, manufacture and
direct marketing of personal care products.
Further experience in the development and
manufacture of pharmaceutical products was obtained through
Robert Rieveley's completion of pharmaceutical industry
courses covering the construction of pharmaceutical facilities
and clean-in-place systems. He has completed the FDA
validation requirement courses for pharmaceutical
manufacturing facilities and clean-in-place systems
construction.
Executive Vice-President, Gale Belding.
B.A.
Gale Belding is responsible for regulatory and
administrative affairs at Biotech. She has previously run a
number of marketing concerns and a successful public relations
company. She is on the board of directors of the West Coast
Women's Network and is past President of the Real Estate
Network. Ms. Belding is actively involved in the coordination
and administration of Biotech's operations.
Chief Financial Officer, Lorne D. Brown,
C.A.
Mr. Brown has had extensive experience in the
design and implementation of financial systems and controls in
private and public companies.
Contacts
Head Office
Suite 160 - 3751 Shell Road
Richmond, British Columbia
Canada, V6X 2W2
Toll Free 1-888-216-1111
Telephone (604) 295-1119
Facsimile (604) 295-1110
SEDAR Filings
BIO filings with SEDAR can be found
here. All
Fillings are current and the Company is fully reporting.
FORWARD LOOKING
STATEMENTS
This report includes forward-looking
statements that reflect Biotech Holdings Ltd. current
expectations about its future results, performance, prospects
and opportunities. Biotech Holdings Ltd. has tried to identify
these forward-looking statements by using words and phrases
such as "may," "will," "expects," "anticipates," "believes,"
"intends," "estimates," "plan," "should," "typical,"
"preliminary," "we are confident" or similar expressions.
These forward-looking statements are based on information
currently available and are subject to a number of risks,
uncertainties and other factors that could cause Biotech
Holdings Ltd.'s actual results, performance, prospects or
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements. These risks,
uncertainties and other factors include, without limitation,
the Company's growth expectations and ongoing funding
requirements, and specifically, the Company's growth prospects
with scalable customers, and those outlined above. Other risks
include the Company's limited operating history, the Company's
history of operating losses, consumers' acceptance, the
Company's use of licensed technologies, risk of increased
competition, the potential need for additional financing, the
terms and conditions of any financing that is consummated, the
limited trading market for the Company's securities, the
possible volatility of the Company's stock price, the
concentration of ownership, and the potential fluctuation in
the Company's operating results.
Disclaimer
AllPennyStocks.com feature stock reports are
intended to be stock ideas, NOT recommendations. Please do
your own research before investing. It is crucial that you at
least look at current SEC filings and read the latest press
releases. Information contained in this report was extracted
from current documents filed with the SEC, the company web
site and other publicly available sources deemed reliable. For
more information see our disclaimer section, a link of which
can be found on our web site. This document contains
forward-looking statements, particularly as related to the
business plans of the Company, within the meaning of Section
27A of the Securities Act of 1933 and Sections 21E of the
Securities Exchange Act of 1934, and are subject to the safe
harbor created by these sections. Actual results may differ
materially from the Company's expectations and estimates. This
is an advertisement for Biotech Holdings Ltd. The purpose of
this advertisement, like any advertising, is to provide
coverage and awareness for the company. The information
provided in this advertisement is not intended for
distribution to, or use by, any person or entity in any
jurisdiction or country where such distribution or use would
be contrary to law or regulation or which would subject us to
any registration requirement within such jurisdiction or
country.
© 1999-2005 AllPennyStocks.com. All rights
reserved. AllPennyStocks.com is not a Registered Broker/Dealer
or Financial Advisor, nor do we hold ourselves out to be. All
materials presented on our web site and individual reports
released to the public through this web site, e-mail or any
other means of transmission are not to be regarded as
investment advice and are only for informative purposes.
Before making a purchase or sale of any securities featured on
our web site or mentioned in our reports, we strongly
encourage and recommend consultation with a registered
securities representative. This is not to be construed as a
solicitation or recommendation to buy or sell securities. As
with any stock, companies we select to profile involve a
degree of investment risk and volatility. Particularly
Small-Caps and OTC-BB stocks. All investors are cautioned that
they may lose all or a portion of their investment if they
decide to make a purchase in any of our profiled companies.
Past performance of our profiled stocks is not indicative of
future results. The accuracy or completeness of the
information on our web site or within our reports is only as
reliable as the sources they were obtained from. The profile
and opinions expressed herein are expressed as of the date the
profile is posted on site and are subject to change without
notice. No investor should assume that reliance on the views,
opinions or recommendations contained herein will produce
profitable results. AllPennyStocks.com may hold positions in
securities mentioned herein, and may make purchases or sales
in such securities featured on our web site or within our
reports. In order to be in full compliance with the Securities
Act of 1933, Section 17(b), AllPennyStocks.com will disclose
in it's disclaimer, what, if any compensation was received for
our efforts in researching, presenting and disseminating this
information to our subscriber database and featuring the
report on the AllPennyStocks.com web site. AllPennyStocks.com
has been compensated nine thousand two hundred dollars from
Biotech Holdings Ltd. for its efforts in presenting the BIOHF
profile on its web site and distributing it to its database of
subscribers as well as other services. AllPennyStocks.com may
decide to purchase or sell shares on a voluntary basis in the
open market before, during or after the profiling period of
this report. As of the profile date, no shares have been sold.
Information presented on our web site and within our reports
contain "forward looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Any statements that
express or involve discussions with respect to predictions,
expectations, beliefs, plans, projections, objectives, goals,
assumptions or future events or performance are not statements
of historical fact and may be "forward looking statements."
Forward looking statements are based on expectations,
estimates and projections at the time the statements are made
that involve a number of risks and uncertainties which could
cause actual results or events to differ materially from those
presently anticipated. Forward looking statements in this
action may be identified through the use of words such as
“expects’”, “will,” “anticipates,” “estimates, “believes,” or
that by statements indicating certain actions “may,” “could,”
or “might” occur.
THE READER SHOULD VERIFY ALL CLAIMS AND DO
THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES
MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE
AND CARRIES A HIGH DEGREE OF RISK.
We encourage our readers to invest carefully
and read the investor information available at the web sites
of the Securities and Exchange Commission (SEC) at:
http://www.sec.gov and/or the National Association of
Securities Dealers (NASD) at:
http://www.nasd.com. Readers can review all public filings
by companies at the SEC's EDGAR page. The NASD has published
information on how to invest carefully at its web site.
